Oncobiologics (OTLK) Expected to Announce Quarterly Earnings on Friday

Oncobiologics (NASDAQ:OTLK) will likely be issuing its Q1 2026 results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $3.1380 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:00 PM ET.

Oncobiologics (NASDAQ:OTLK) last posted its earnings results on Friday, December 19th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $4.65 million during the quarter, compared to analyst estimates of $5.85 million. On average, analysts expect Oncobiologics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncobiologics Price Performance

Shares of Oncobiologics stock opened at $0.39 on Friday. Oncobiologics has a 1-year low of $0.39 and a 1-year high of $3.39. The business’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.43. The company has a market capitalization of $28.67 million, a P/E ratio of -0.26 and a beta of 0.10.

Institutional Investors Weigh In On Oncobiologics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its holdings in shares of Oncobiologics by 74.1% during the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after acquiring an additional 44,063 shares during the period. AQR Capital Management LLC boosted its stake in Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on OTLK shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a report on Monday, December 29th. Wall Street Zen downgraded shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Finally, Ascendiant Capital Markets upped their price target on shares of Oncobiologics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Oncobiologics has a consensus rating of “Hold” and an average target price of $5.33.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.